<DOC>
	<DOC>NCT01859702</DOC>
	<brief_summary>The purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug Vigadexa preoperatively in cataract patients.</brief_summary>
	<brief_title>Pharmacokinetic Evaluation of Moxifloxacin in VigadexaÂ® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Requires cataract surgery; Acceptable health status (medical history, physical, laboratory and ophthalmologic exams); Able to follow instructions and willing to attend all study visits; Other protocoldefined inclusion criteria may apply. Any known or suspected allergies/hypersensitivity to any of the investigational test product components; History of invasive intraocular surgery in the eye to be operated, within 4 months before enrollment; Use of medications, as specified in protocol; Severe dry eye syndrome; Use of contact lenses two days before surgery until the last visit; External eye disease, infection or inflammation of the eyes or eyelids; Excessive bleeding tendency; No vision in the eye not included in the study; Pregnant or breastfeeding; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Aqueous Humor</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Vigadexa</keyword>
</DOC>